Cibc World Market Inc. Has $137.02 Million Position in Merck & Co., Inc. $MRK

Cibc World Market Inc. boosted its position in Merck & Co., Inc. (NYSE:MRK) by 32.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,301,744 shares of the company’s stock after purchasing an additional 320,143 shares during the period. Cibc World Market Inc.’s holdings in Merck & Co., Inc. were worth $137,022,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Kingdom Financial Group LLC. acquired a new position in Merck & Co., Inc. in the 4th quarter worth about $25,000. High Note Wealth LLC increased its holdings in Merck & Co., Inc. by 58.9% in the 4th quarter. High Note Wealth LLC now owns 294 shares of the company’s stock worth $31,000 after purchasing an additional 109 shares in the last quarter. Tucker Asset Management LLC acquired a new position in Merck & Co., Inc. in the 4th quarter worth about $34,000. Entrust Financial LLC acquired a new position in Merck & Co., Inc. in the 4th quarter worth about $37,000. Finally, United Financial Planning Group LLC acquired a new position in Merck & Co., Inc. in the 3rd quarter worth about $31,000. Institutional investors and hedge funds own 76.07% of the company’s stock.

Merck & Co., Inc. News Roundup

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Analysts have been raising Merck price targets, with some moving estimates from $135 to $150, as optimism builds around pipeline assets such as Sac TMT and TERN-701. This suggests Wall Street sees more upside if key trials and deal terms develop favorably. How Recent Pipeline Bets Are Rewriting the Story for Merck (MRK)
• Positive Sentiment: Merck received FDA breakthrough therapy designation for calderasib, a potential sign of regulatory momentum for one of its pipeline programs. That kind of update can support sentiment by improving the odds of future commercialization. Merck & Co. (MRK) Announces FDA’s Grant of Breakthrough Therapy Designation for Calderasib
• Positive Sentiment: Merck continues to highlight its oncology strategy and clinical pipeline at ASCO and other healthcare conferences, which keeps investors focused on longer-term growth opportunities beyond Keytruda. Merck & Co., Inc. (MRK) Presents at American Society of Clinical Oncology (ASCO) Annual Meeting 2026 – Slideshow
• Neutral Sentiment: Merck also announced a quarterly dividend and participated in investor-conference coverage, both of which reinforce its stable income profile and keep the company in focus, but are not major near-term catalysts. Merck & Co. (MRK) Announces Quarterly Dividend Merck to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
• Negative Sentiment: Some articles compare Merck unfavorably with peers or suggest the stock may not be the top biotech winner this year, which can weigh on sentiment if investors rotate toward faster-growing names. Meet the Biotech Stock That’s Trouncing Lilly, Merck, and Pfizer in 2026
• Negative Sentiment: Merck’s recent notes offering may strengthen its capital structure, but debt issuance can also remind investors of balance-sheet leverage and financing needs. Merck (MRK) Strengthens Capital Structure With Notes Offering

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the company. Royal Bank Of Canada reiterated an “outperform” rating and issued a $142.00 price target on shares of Merck & Co., Inc. in a research report on Monday, March 30th. Deutsche Bank Aktiengesellschaft upgraded Merck & Co., Inc. from a “hold” rating to a “buy” rating and set a $150.00 price target on the stock in a research report on Friday, February 13th. UBS Group upped their price target on Merck & Co., Inc. from $130.00 to $145.00 and gave the company a “buy” rating in a research report on Monday, April 13th. Guggenheim upped their price target on Merck & Co., Inc. from $122.00 to $140.00 and gave the company a “buy” rating in a research report on Friday, February 6th. Finally, Cantor Fitzgerald upped their price target on Merck & Co., Inc. from $116.00 to $120.00 and gave the company a “neutral” rating in a research report on Wednesday, February 4th. One investment analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and seven have issued a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $128.18.

Merck & Co., Inc. Stock Down 0.6%

Shares of Merck & Co., Inc. stock opened at $114.92 on Thursday. Merck & Co., Inc. has a one year low of $76.66 and a one year high of $125.14. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.30 and a quick ratio of 1.06. The stock’s 50-day moving average is $116.44 and its 200 day moving average is $112.13. The firm has a market cap of $283.84 billion, a price-to-earnings ratio of 32.37, a PEG ratio of 2.60 and a beta of 0.21.

Merck & Co., Inc. (NYSE:MRK) last announced its earnings results on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, beating the consensus estimate of ($1.47) by $0.19. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The company had revenue of $16.29 billion for the quarter, compared to analyst estimates of $15.85 billion. During the same quarter in the prior year, the company earned $2.22 EPS. The firm’s revenue for the quarter was up 4.9% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. Equities research analysts anticipate that Merck & Co., Inc. will post 5.16 EPS for the current year.

Merck & Co., Inc. Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, July 8th. Investors of record on Monday, June 15th will be given a dividend of $0.85 per share. The ex-dividend date is Monday, June 15th. This represents a $3.40 annualized dividend and a dividend yield of 3.0%. Merck & Co., Inc.’s dividend payout ratio is presently 95.77%.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.